Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Completed 3Withdrawn 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 4

Conditions

Colorectal Neoplasms 234Carcinoma, Non-Small-Cell Lung 132Breast Neoplasms 121Glioblastoma 88Ovarian Neoplasms 86Carcinoma, Hepatocellular 69Rectal Neoplasms 64Brain Neoplasms 58Lung Neoplasms 55Neoplasm Metastasis 54Neoplasms 52Colonic Neoplasms 50Fallopian Tube Neoplasms 43Glioma 40Carcinoma, Renal Cell 35Gliosarcoma 34Melanoma 26Adenocarcinoma of Lung 26Pancreatic Neoplasms 23Liver Neoplasms 23Uterine Cervical Neoplasms 21Stomach Neoplasms 21Recurrence 21Triple Negative Breast Neoplasms 18Kidney Neoplasms 16Endometrial Neoplasms 16Esophageal Neoplasms 15Astrocytoma 14Carcinoma, Ovarian Epithelial 13Adenocarcinoma, Bronchiolo-Alveolar 13

Interventions

Gemcitabine 9Carboplatin 8Paclitaxel 6Capecitabine 4Bevacizumab 4pembrolizumab 3Irinotecan 3Erlotinib Hydrochloride 3atezolizumab 2Peripheral Blood Stem Cell Transplantation 2Oxaliplatin 2Filgrastim 2Cisplatin 2CP protocol 2tislelizumab 1tegafur-gimeracil-oteracil 1spartalizumab 1sintilimab 1pertuzumab 1pemigatinib 1olaparib 1ivosidenib 1ipatasertib 1etoposide phosphate 1entrectinib 1cobimetinib 1belinostat 1antineoplaston AS 2-1 1antineoplaston A10 1alectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms, Unknown Primary × Bevacizumab × Clear all
NCT03498521 2025-11-19

CUPISCO

Hoffmann-La Roche

Phase 2 Completed
529 enrolled 16 charts
Tumor-Agnostic

Neoplasms, Unknown Primary

NCT00458315 2015-05-08

Cisplatin/Paclitaxel/Gemcitabine +/- Avastin in Patients With Unknown Primary Tumor

Rigshospitalet, Denmark

Phase 2 Withdrawn
Tumor-Agnostic

Neoplasms, Unknown Primary

NCT00360360 2013-12-04

Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site

SCRI Development Innovations, LLC

Phase 2 Completed
60 enrolled 6 charts
Tumor-Agnostic

Neoplasms, Unknown Primary

NCT00193622 2010-09-17

Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site

SCRI Development Innovations, LLC

Phase 2 Completed
50 enrolled
Tumor-Agnostic

Neoplasms, Unknown Primary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡